This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Back to Drug Candidates

Olaparib

Lynparza

PARP inhibitor

Evidence Score

45

theoretical
Mechanism of Action

Inhibits PARP1/2 enzymes involved in DNA single-strand break repair. In cells with elevated ROS (like SDH-deficient cells), increased DNA damage combined with PARP inhibition may create synthetic lethality by overwhelming DNA repair capacity.

Pathway Connections
Oxidative Stress / ROS

Complex II dysfunction causes electron leak in the electron transport chain, increasing reactive oxygen species (ROS). This drives DNA damage but also creates a therapeutic vulnerability.

Upstream event:

Impaired electron flow through Complex II → electron leak

Downstream effects:

Increased ROS productionOxidative DNA damageGenomic instabilityPARP activation for DNA repairTherapeutic vulnerability to further ROS stress
Molecular Targets

PARP1

Poly(ADP-ribose) polymerase 1

synthetic_lethal

DNA repair enzyme activated by ROS-induced damage. PARP inhibition in ROS-elevated cells may cause synthetic lethality.

UniProt: P09874

Quick Facts
FDA Approved

Approved Indications

  • BRCA-mutated ovarian cancer
  • BRCA-mutated breast cancer
  • BRCA-mutated pancreatic cancer
  • HRD-positive prostate cancer
ChEMBL IDCHEMBL521686
PubChem CID23725625
Evidence

Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.

Coming in Phase 3

For research exploration only — not medical advice. Consult your doctor before acting on any information.

AI Analysis

Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.